StreetInsider.com News Articles

Bio-Techne opens GMP manufacturing facility in Bristol, UK

Thu, 08 Oct 2026 08:01:59 -0400

Bio-Techne Corporation (NASDAQ: TECH) has opened a new Good Manufacturing Practice (GMP) small molecule manufacturing facility in Bristol, United Kingdom, according to a company press release dated Oct. 8, 2026.

The purpose-built 10,000-square-foot facility includes five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. The company states the facility is fully operational.

The Bristol site adds to Bio-Techne's existing manufacturing operations, which include recombinant protein manufacturing in Minneapolis, Minnesota, GMP capabilities in St. Paul, Minnesota, and a relationship with Wilson Wolf Corporation, a manufacturer of cell culture devices including the G-Rex® platform.

"As the cell

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Thu, 08 Oct 2026 08:00:00 -0400

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications
New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Thu, 08 Oct 2026 08:00:00 -0400

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications
New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America

Mizuho sees biopharma funding rise 56% in September on public deals

Fri, 02 Oct 2026 06:31:11 -0400

Investing.com - Biopharma funding totaled $13.0 billion in September 2026, up 42% from $9.1 billion in August and 56% higher than the prior year, according to BioWorld data highlighted by Mizuho. Public-other financing accounted for 64% of September funding, rising 75% month-over-month and 272% year-over-year.

Year-to-date biopharma funding reached $89.1 billion through September, up 84% from $48.3 billion in the same period of 2025. IPOs saw the largest year-over-year increase at 281%, followed by follow-on offerings at 159% and public-other financing at 53%. Venture funding posted the smallest gain at 25% year-over-year.

Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from

Mizuho sees biopharma funding rise 56% in September on public deals

Fri, 02 Oct 2026 06:31:11 -0400

Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from

Mizuho sees biopharma funding rise 56% in September on public deals

Fri, 02 Oct 2026 06:31:11 -0400

Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from

Mizuho sees biopharma funding rise 56% in September on public deals

Fri, 02 Oct 2026 06:31:11 -0400

Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from

Form 4 BIO-TECHNE Corp For: Sep 28 Filed by: HIGGINS JOHN L

Wed, 30 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260930/27128795.html

Form 4 BIO-TECHNE Corp For: Sep 22 Filed by: BAUMGARTNER ROBERT V

Thu, 24 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260924/27102757.html

Form 8-K BIO-TECHNE Corp For: Sep 23

Wed, 23 Sep 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260923/27097371.html

Bio-Techne shareholders vote to approve Merck KGaA acquisition

Wed, 23 Sep 2026 09:21:28 -0400

Bio-Techne Corporation (NASDAQ: TECH) shareholders voted to approve the proposed acquisition of the company by Merck KGaA, Darmstadt, Germany at a Special Meeting of Shareholders held Sept. 23, 2026.

The final voting results, as certified by an independent inspector of elections, will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.

The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 11:59 p.m. Eastern Time on Sept. 18, 2026, clearing another condition for the deal to proceed.

Bio-Techne said it expects the transaction to close by late 2026 or early 2027, subject to satisfaction of customary

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Wed, 23 Sep 2026 09:20:00 -0400

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Wed, 23 Sep 2026 09:20:00 -0400

Bio-Techne opens customer experience center in Düsseldorf

Tue, 22 Sep 2026 09:05:09 -0400

Bio-Techne Corporation (NASDAQ: TECH) has opened a Customer Experience Center in Düsseldorf, Germany, establishing a regional hub for researchers and organizations across the DACH region and the broader Europe, Middle East and Africa region.

The facility, housed in a refurbished building with energy-efficient features, is designed to give visitors hands-on access to Bio-Techne technologies and workflows across areas including protein biology, spatial biology, cell therapy, molecular diagnostics and analytical instrumentation. The center will also host workshops, technical training programs and thought leadership events.

According to the company's press release, the center is intended to serve researchers, biopharmaceutical companies, biotechnology innovators and clinical

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

Tue, 22 Sep 2026 09:00:00 -0400

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise
Regional hub will support researchers and organizations across the DACH and broader EMEA regions

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

Tue, 22 Sep 2026 09:00:00 -0400

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise
Regional hub will support researchers and organizations across the DACH and broader EMEA regions

Form DEFA14A BIO-TECHNE Corp

Mon, 14 Sep 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260914/27059036.html

Form 8-K BIO-TECHNE Corp For: Sep 14

Mon, 14 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260914/27059028.html

Form DEFA14A BIO-TECHNE Corp

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975051.html

Form DEFA14A BIO-TECHNE Corp

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975051.html

Form 10-K BIO-TECHNE Corp For: Jun 30

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968536.html

Form 10-K BIO-TECHNE Corp For: Jun 30

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968536.html

Form DEFM14A BIO-TECHNE Corp

Thu, 20 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260820/26957205.html

Form DEFM14A BIO-TECHNE Corp

Thu, 20 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260820/26957205.html

Form 4 BIO-TECHNE Corp For: Aug 17 Filed by: Kelderman Kim

Wed, 19 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260819/26950803.html